$1.52 Billion is the total value of Casdin Capital, LLC's 37 reported holdings in Q3 2022. The portfolio turnover from Q2 2022 to Q3 2022 was 63.6% .
Value | Shares | ↓ Weighting | ||||||
---|---|---|---|---|---|---|---|---|
SRPT | Buy | SAREPTA THERAPEUTICS INC | $135,412,000 | +177.9% | 1,225,000 | +88.5% | 8.90% | +115.9% |
BPMC | Buy | BLUEPRINT MEDICINES CORP | $112,013,000 | +92.8% | 1,700,000 | +47.8% | 7.36% | +49.8% |
VERV | Buy | VERVE THERAPEUTICS INC | $109,170,000 | +127.7% | 3,178,167 | +1.3% | 7.17% | +76.9% |
RLAY | Buy | RELAY THERAPEUTICS INC | $104,768,000 | +53.7% | 4,683,432 | +15.1% | 6.88% | +19.4% |
ILMN | New | ILLUMINA INC | $73,454,000 | – | 385,000 | +100.0% | 4.82% | – |
RVMD | Buy | REVOLUTION MEDICINES INC | $49,740,000 | +7.7% | 2,522,300 | +6.4% | 3.27% | -16.4% |
Buy | SOMALOGIC INC | $36,552,000 | -34.7% | 12,604,275 | +1.7% | 2.40% | -49.3% | |
EXAS | Buy | EXACT SCIENCES CORP | $31,418,000 | +77.2% | 967,000 | +114.9% | 2.06% | +37.7% |
MRTX | Buy | MIRATI THERAPEUTICS INC | $17,460,000 | +168.1% | 250,000 | +157.7% | 1.15% | +108.2% |
NTLA | New | INTELLIA THERAPEUTICS INC | $16,508,000 | – | 295,000 | +100.0% | 1.08% | – |
ABCL | Buy | ABCELLERA BIOLOGICS INC | $16,319,000 | +104.3% | 1,650,000 | +120.0% | 1.07% | +58.8% |
PLRX | New | PLIANT THERAPEUTICS INC | $15,668,000 | – | 750,000 | +100.0% | 1.03% | – |
ARVN | New | ARVINAS INC | $8,898,000 | – | 200,000 | +100.0% | 0.58% | – |
MRTX | New | MIRATI THERAPEUTICS INCcall | $6,984,000 | – | 100,000 | +100.0% | 0.46% | – |
MRNA | New | MODERNA INC | $3,843,000 | – | 32,500 | +100.0% | 0.25% | – |
OMIC | Buy | SINGULAR GENOMICS SYSTEMS IN | $3,364,000 | +1.7% | 1,345,722 | +55.4% | 0.22% | -21.1% |
NVTA | Buy | INVITAE CORP | $2,770,000 | +9.3% | 1,125,888 | +8.4% | 0.18% | -15.0% |
CERE | New | CEREVEL THERAPEUTICS HLDNG I | $2,261,000 | – | 80,000 | +100.0% | 0.15% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2022-11-14
Top long-term holdings
Name | Quarters owned | Latest quarter owned | Max weighting |
---|---|---|---|
BLUEPRINT MEDICINES CORP | 35 | Q2 2024 | 9.6% |
ALNYLAM PHARMACEUTICALS INC | 35 | Q2 2024 | 9.9% |
AGIOS PHARMACEUTICALS INC | 27 | Q2 2022 | 12.1% |
FATE THERAPEUTICS INC | 27 | Q4 2023 | 8.3% |
GLOBAL BLOOD THERAPEUTICS IN | 27 | Q2 2022 | 7.1% |
BIOLIFE SOLUTIONS INC | 25 | Q2 2024 | 14.9% |
CODEXIS INC | 25 | Q2 2024 | 8.1% |
SAREPTA THERAPEUTICS INC | 24 | Q2 2024 | 13.6% |
ILLUMINA INC | 24 | Q2 2024 | 6.0% |
DENALI THERAPEUTICS INC | 23 | Q2 2024 | 3.7% |
View Casdin Capital, LLC's complete holdings history.
Latest significant ownerships (13-D/G)
Filed | Shares | Percentage | |
---|---|---|---|
Century Therapeutics, Inc. | April 18, 2024 | 5,190,506 | 6.1% |
MAXCYTE, INC.Sold out | February 14, 2024 | 0 | 0.0% |
Relay Therapeutics, Inc. | February 14, 2024 | 7,387,943 | 6.0% |
EQRx, Inc.Sold out | November 15, 2023 | 0 | 0.0% |
BIOLIFE SOLUTIONS INC | October 24, 2023 | 8,707,165 | 19.5% |
Absci Corp | May 08, 2023 | 4,448,260 | 4.8% |
CODEXIS, INC.Sold out | February 14, 2023 | 0 | 0.0% |
DermTech, Inc.Sold out | February 14, 2023 | 0 | 0.0% |
Invitae Corp | February 14, 2023 | 9,038,388 | 3.7% |
Magenta Therapeutics, Inc.Sold out | February 14, 2023 | 0 | 0.0% |
View Casdin Capital, LLC's complete significant-ownership history.
Latest filings
Type | Filed |
---|---|
N-PX | 2024-09-03 |
4 | 2024-08-29 |
4 | 2024-08-26 |
4 | 2024-08-21 |
4 | 2024-08-16 |
13F-HR | 2024-08-14 |
SC 13D/A | 2024-08-14 |
4 | 2024-08-13 |
4 | 2024-08-09 |
4 | 2024-08-06 |
View Casdin Capital, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.